BCR/ABL1–like acute lymphoblastic leukemia: How to diagnose and treat? - Chiaretti - 2019 - Cancer - Wiley Online Library
HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia | Leukemia
Major Molecular Response Achievement in CML Patients Can Be Predicted by BCR -ABL1/ABL1 or BCR-ABL1/GUS Ratio at an Earlier Time Point of Follow-Up than Currently Recommended | PLOS ONE
Is the BCR-ABL/GUSB transcript level at diagnosis an early predictive marker for chronic myeloid leukemia patients treated with imatinib? – ScienceOpen
Frontiers | Genomic Copy Number Variants in CML Patients With the Philadelphia Chromosome (Ph+): An Update
Measurable residual disease in chronic myeloid leukemia | Haematologica
The Philadelphia chromosome in leukemogenesis | Cancer Communications | Full Text
BCR/ABL1–like acute lymphoblastic leukemia: How to diagnose and treat? - Chiaretti - 2019 - Cancer - Wiley Online Library
Cancers | Free Full-Text | Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia
Frontiers | BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
The Philadelphia chromosome in leukemogenesis | Cancer Communications | Full Text
Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission | Leukemia
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease | Leukemia
Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes - ScienceDirect
Response and Resistance to BCR-ABL1-Targeted Therapies - ScienceDirect
Myeloproliferative neoplasms with concurrent BCR–ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group | Modern Pathology
IVD Antibody Development Services for BCR-ABL Marker - Creative Biolabs
Multiplex PCR of BCR-ABL1 transcript variants in CML patients... | Download Scientific Diagram
Change in BCR-ABL1 IS over time based on achievement of BCR-ABL1 IS 10%... | Download Scientific Diagram
Structure of the BCR/ABL1 oncogene. (A) Schematic representation of the... | Download Scientific Diagram
Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques | PLOS ONE
Cancers | Free Full-Text | Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
Precision Medicine in BCR-ABL1 Negative Myeloproliferative Neoplasms | Published in healthbook TIMES Oncology Hematology
Frontiers | A Review on the Therapeutic Role of TKIs in Case of CML in Combination With Epigenetic Drugs
Persistence of LSCs: BCR-ABL1 kinase-dependent and -independent pathways. | Download Scientific Diagram
